Mega CapHealthcareDividend

JNJ — Johnson & Johnson

Pharmaceuticals / MedTech · Founded 1886 · New Brunswick, New Jersey · CEO: Joaquin Duato

Johnson & Johnson is a global healthcare company operating in pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Following the spin-off of its consumer health division as Kenvue in 2023, JNJ is now focused on higher-growth, higher-margin healthcare segments.

How Johnson & Johnson Makes Money

Innovative Medicine (pharmaceuticals) — key drugs in immunology, oncology, neuroscience, and cardiovascular

MedTech — surgical instruments, orthopedics, vision care (contact lenses), and interventional solutions

Licensing and royalty income from patent portfolios

Key Metrics Investors Watch

Pharmaceutical pipeline progress and new drug launches
Revenue growth in key drug franchises
MedTech procedure volume trends
Patent cliff exposure and biosimilar competition timelines
Free cash flow and dividend sustainability

Competitive Advantages

One of the strongest pharmaceutical pipelines in the industry with multiple blockbuster drugs
AAA credit rating — one of only two US companies (with Microsoft) to hold the top rating
Global scale across pharmaceuticals and medical devices provides diversification
60+ consecutive years of dividend increases (Dividend King status)

Key Risks

Patent cliffs on key drugs expose revenue to biosimilar and generic competition
Litigation risk including talc-related lawsuits (multibillion-dollar potential liability)
Drug pricing reform legislation could pressure pharmaceutical margins
Competition from biotech companies with innovative therapies

Dividend & Capital Return

JNJ is a Dividend King with 60+ consecutive years of dividend increases. The stock is a staple of income-focused portfolios.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

Is Johnson & Johnson stock a good investment?

JNJ is considered a defensive blue-chip stock with a strong dividend track record. The post-Kenvue spin-off company is more focused on higher-growth pharmaceuticals and MedTech. This is educational content, not financial advice.

How does Johnson & Johnson make money?

JNJ generates revenue from pharmaceuticals (Innovative Medicine segment) and medical devices (MedTech). Key drug areas include immunology, oncology, and neuroscience.

What happened to JNJ's consumer products?

JNJ spun off its consumer health business as a separate public company called Kenvue (KVUE) in 2023. Brands like Band-Aid, Tylenol, and Neutrogena are now under Kenvue.

Does JNJ pay a dividend?

Yes, JNJ is a Dividend King with more than 60 consecutive years of dividend increases. It is one of the most reliable dividend stocks in the market.

What are JNJ's biggest risks?

Key risks include patent expirations on major drugs, ongoing talc litigation liability, drug pricing reform, and competition from biotech companies.

Related Stocks

ABBV

AbbVie Inc.

Healthcare

AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and eye care. Spun off from Abbott Laboratories in 2013, AbbVie is best known for Humira (the world's best-selling drug of all time) and its successor drugs Skyrizi and Rinvoq.

MRK

Merck & Co., Inc.

Healthcare

Merck is a global pharmaceutical and animal health company known for Keytruda, the world's best-selling cancer immunotherapy drug. The company has a strong pipeline in oncology, vaccines, and cardiometabolic diseases and operates one of the largest animal health businesses globally.

LLY

Eli Lilly and Company

Healthcare

Eli Lilly is a global pharmaceutical company at the center of the GLP-1 / obesity drug revolution. Mounjaro (tirzepatide) for diabetes and Zepbound for weight loss have made Lilly one of the fastest-growing and most valuable pharmaceutical companies in the world.

PFE

Pfizer Inc.

Healthcare

Pfizer is one of the world's largest pharmaceutical companies, with a diversified portfolio spanning oncology, immunology, rare diseases, vaccines, and hospital medicines. The company became globally prominent during the COVID-19 pandemic through its co-developed mRNA vaccine (Comirnaty) with BioNTech and antiviral pill Paxlovid. Post-pandemic, Pfizer has focused on restoring growth through acquisitions including Seagen (oncology) and deploying its substantial cash reserves. The company faces significant patent cliffs on several major drugs in the late 2020s.

Recommended Resources

Tools & books I actually use and recommend

SeekingAlpha Premium

Quant ratings, earnings transcripts, and the stock analysis community where I published 300+ articles.

Try SeekingAlpha

The Intelligent Investor

Ben Graham's timeless guide to value investing. The book Warren Buffett calls "the best investing book ever written."

View on Amazon

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.